This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Intarcia Therapeutics, Inc.
Drug Names(s): ITCA-650, ITCA650, DUROS continuous delivery of exenatide
Description: ITCA 650 involves the delivery of exenatide (Byetta), an approved incretin mimetic, with the subcutaneous DUROS delivery device, a 4 mm x 45 mm subcutaneous osmotic mini-pump. ITCA 650 is designed to deliver a continuous and constant dose of exenatide over an extended period of time.
Alza & Intarcia
DUROS is a registered trademark of Alza licensed to IntarciaTherapeutics in certain fields.
Alza and Johnson & Johnson
Alza was acquired by Johnson and Johnson in 2001.
Intarcia & Quintiles
In December 2011, Intarcia Therapeutics and Quintiles announced the signing of definitive agreements whereby Quintiles will become a financial and strategic partner for the global clinical development of ITCA 650. Through this alliance, Quintiles will support the accelerated development of ITCA 650 by its Capital Solutions group providing a combination of equity, product, and operational investments. Per an Intarcia representative, Quintiles does not receive royalties.
Intarcia & Servier
In November 2014, Intarcia announced the start of a strategic partnership with Servier outside the United States and Japan, to develop and commercialize ITCA 650. Under the agreement, Intarcia is to receive an upfront payment and total...See full deal structure in Biomedtracker
Partners: Johnson & Johnson Quintiles Transnational Holdings, Inc. Les Laboratoires Servier
ITCA 650 News
Additional information available to subscribers only: